Li-Huei Tsai
Corporate Officer/Principal bei The Broad Institute, Inc.
Profil
Li-Huei Tsai is the founder of Cognito Therapeutics, Inc. She currently holds positions as Director-Picower Institute for Learning & Memory at Massachusetts Institute of Technology, Member at The Broad Institute, Inc., and Member at National Academy of Medicine.
Her former positions include Independent Director at International Flavors & Fragrances, Inc. from 2019 to 2021, and Professor at Harvard Medical School from 1994 to 2006.
She earned a doctorate degree from The University of Texas Southwestern Medical Center.
Aktive Positionen von Li-Huei Tsai
| Unternehmen | Position | Beginn |
|---|---|---|
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
| National Academy of Medicine | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Li-Huei Tsai
| Unternehmen | Position | Ende |
|---|---|---|
| INTERNATIONAL FLAVORS & FRAGRANCES INC. | Direktor/Vorstandsmitglied | 01.02.2021 |
| Harvard Medical School | Corporate Officer/Principal | 01.01.2006 |
Cognito Therapeutics, Inc.
 Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Gründer | - |
Ausbildung von Li-Huei Tsai
| The University of Texas Southwestern Medical Center | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INTERNATIONAL FLAVORS & FRAGRANCES INC. | Consumer Non-Durables |
| Private Unternehmen | 3 |
|---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Cognito Therapeutics, Inc.
Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Health Technology |
| National Academy of Medicine |
